How AI Is Transforming Scientific Discovery in 2026

AI-Powered Protein Science

AlphaFold 2 (DeepMind, 2020): solved the 50-year protein folding problem — median GDT >90 at CASP14. AlphaFold Database: >200 million predicted structures covering virtually all known proteins. Nobel Prize 2024 awarded to Demis Hassabis and John Jumper. AlphaFold 3 (2024): predicts complexes of proteins with DNA, RNA, ligands, and ions — unified architecture for biomolecular structure. ESMFold (Meta AI): single-sequence prediction in seconds (no MSA needed). RFdiffusion (Baker Lab): generates novel protein structures from scratch — de novo protein design enters a new era. Practical impact: accelerating drug target identification, enzyme engineering for industrial catalysis, and vaccine design.

Materials Discovery at Scale

GNoME (Google DeepMind, 2023): discovered 2.2 million new stable crystal structures — 10× more than previously known. 380,000 of these are on the convex hull (thermodynamically stable), ready for experimental validation. A-Lab (Berkeley): robotic lab that autonomously synthesizes new materials — 43 out of 58 AI-suggested materials successfully made in 17 days. MatterGen (Microsoft): generative AI for materials — designs crystals with specified properties (bandgap, conductivity, stability). DARWIN (Liverpool): mobile robot chemist that autonomously plans and executes experiments. Applications: solid-state electrolytes for safer batteries, photocatalysts for green hydrogen, thermoelectric materials for waste heat recovery.

Drug Discovery Reimagined

Traditional drug development: 10-15 years, $2.6 billion per approved drug, 90% failure rate in clinical trials. AI-discovered drugs in clinical trials: Insilico Medicine's INS018_055 for idiopathic pulmonary fibrosis (Phase II) — discovered and designed in 18 months. Recursion Pharmaceuticals: AI-driven drug repurposing and discovery, $600M+ raised. Isomorphic Labs (DeepMind spin-off): multi-billion dollar partnerships with Eli Lilly and Novartis. AlphaFold's impact on drug design: knowing 3D structure of disease targets enables rational drug design. Generative chemistry: diffusion models generate novel drug molecules with desired properties (binding affinity, ADMET profile). Clinical trial optimization: AI predicts patient response, identifies biomarkers, designs adaptive trials. Virtual screening: AI evaluates billions of molecular candidates in hours vs. months for traditional high-throughput screening.

Autonomous Laboratories

Self-driving labs: fully automated experimental workflows — hypothesis generation, experiment design, execution, analysis, iteration. Emerald Cloud Lab: commercial automated lab accessible via API — researchers write code, robots execute experiments. The Artificial Chemist (NC State): autonomously optimizes quantum dot synthesis — 6× faster than manual optimization. BioFoundry platforms: automated DNA assembly, strain engineering, metabolic pathway optimization. Large language models in science: GPT-4, Claude, and Gemini assist with literature review, hypothesis generation, and experimental design. SciML: physics-informed neural networks that respect conservation laws and known equations. Challenges: reproducibility (AI must document reasoning), data quality, and the "black box" problem. Future: fully autonomous research cycles where AI identifies knowledge gaps, designs experiments, and publishes findings — human scientists shift to strategic direction and creativity.

Try it live

Everything above runs in your browser — open AI Protein Folding & Autonomous Discovery Lab and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.